EXHIBIT 99(c)

FOR IMMEDIATE RELEASE

            ARTHUR F. RYAN ELECTED TO REGENERON'S BOARD OF DIRECTORS

Tarrytown, NY (January 17, 2003) - Regeneron Pharmaceuticals, Inc. (Nasdaq:
REGN) announced today that it has elected Arthur F. Ryan to fill a new seat on
its expanded Board of Directors. Mr. Ryan is Chairman, Chief Executive Officer,
and President of Prudential Financial, Inc., one of the largest diversified
financial institutions in the world.

"Art brings extraordinarily important strategic and financial leadership skills
to our Board," noted P. Roy Vagelos, M.D., Chairman of Regeneron's Board of
Directors. "With our broad therapeutic pipeline and emerging opportunities for
several product candidates, we'll benefit from Art's significant experience in
managing complex businesses. He'll help us plan Regeneron's business growth.
We're delighted to have Art join our Board."

Mr. Ryan joined Prudential in December 1994, and he led the company's strategic
conversion from a mutual to a publicly traded company in 2001. Prior to joining
Prudential in December 1994, he had been President and Chief Operating Officer
of Chase Manhattan Bank since 1990. Mr. Ryan ran Chase's worldwide retail bank
between 1984 and 1990.

Regeneron is a biopharmaceutical company that discovers, develops, and intends
to commercialize therapeutic medicines for the treatment of serious medical
conditions. Regeneron has therapeutic candidates for the potential treatment of
obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs
in other diseases and disorders.

This news release discusses historical information and includes forward-looking
statements about Regeneron and its products, programs, finances, and business,
all of which involve a number of risks and uncertainties, such as risks
associated with preclinical and clinical development of drugs and biologics,
determinations by regulatory and administrative governmental authorities,
competitive factors, technological developments, the availability and cost of
capital, the costs of developing, producing, and selling products, the potential
for any collaboration agreement to be canceled or to terminate without any
product success, and other material risks. A more complete description of these
risks can be found in Regeneron's filings with the United States Securities and
Exchange Commission, including its Form 10-K for the year ended December 31,
2001 and the Form 10-Q for the quarter ended September 30, 2002. Regeneron does
not undertake any obligation to update publicly any forward-looking statement,
whether as a result of new information, future events, or otherwise, unless
required by law.

                                       -8-